BioSpace News Archive

Philogen S.p.A. announces that it has entered into a Clinical Trial Collaboration and Supply Agreement with MSD.

Gradient Denervation Technologies, a Paris-based medical device company developing a minimally-invasive device for treating certain heart failure patients with associated pulmonary hypertension, announced the successful first patient enrollment in its first-in-human clinical study.

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that company management will participate in the following conferences and invited investors to participate by webcast.

Amarin Corporation plc announced that its commercial partner in China, EddingPharm, has received regulatory approval for VASCEPA® from China’s National Medical Products Administration.

REALM IDx announced the launch of REALM Pharma Services, an end-to-end discovery, translational research, and clinical trial service for biotechnology and pharmaceutical partners.

Caris Life Sciences® and ConcertAI announced an expanded translational sciences and clinical development solutions partnership.

AstraZeneca and Merck, known as MSD outside of the United States and Canada, announced that LYNPARZA in combination with abiraterone and prednisone or prednisolone has been approved by the U.S. Food and Drug Administration for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer.

ASLAN Pharmaceuticals announced that management will present a company update at the Jefferies Global Healthcare Conference, to be held in-person in New York, NY, from June 7 to 9, 2023.

BioCryst Pharmaceuticals, Inc. announced that the company will present at the Jefferies Healthcare Conference on Wednesday, June 7th at 4:30 p.m. ET in New York.

BioXcel Therapeutics, Inc. announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will participate in fireside chats at two upcoming investor conferences.